Intestinal permeability and immune‐inflammatory markers in patients with idiosyncratic drug‐induced liver injury, drug‐induced steatosis and metabolic dysfunction–associated steatotic liver disease (MASLD)
British Journal of Pharmacology · 2025-11 · 182 (21) · 5303-5316
DOI: 10.1111/bph.70123 ↗At a glance
Journal article in British Journal of Pharmacology, published online on 2025-06-25. Written by Daniel E Di Zeo-Sánchez and 10 co-authors. Institution: UGC Aparato Digestivo, Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Vi…. Major MEDLINE topics: Chemical and Drug Induced Liver Injury, Fatty Liver, Intestinal Mucosa. Cited 6 times so far (Crossref); 75 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Sara Borrell Research Contract (ISCIII), HORIZON-HLTH-2022-STAYHLTH-02, Instituto de Salud Carlos III - European Union and Fondo Europeo de Desarrollo Regional - FEDER.
Abstract (original language)
Background and Purpose Adverse immuno‐inflammatory responses possibly influenced by bacterial compounds reaching the liver as a consequence of altered intestinal permeability appear to be crucial in the pathogenesis of drug‐induced liver injury and steatotic liver diseases. This study aimed to assess intestinal permeability and immuno‐inflammatory status in patients by measuring indirect biomarkers. Experimental Approach Circulating marker levels were measured in serum and plasma samples of 36 healthy controls, 32 patients with drug‐induced liver injury, 14 with autoimmune hepatitis, 13 with viral hepatitis, 40 with metabolic dysfunction–associated steatotic liver disease (MASLD) and 16 with drug‐induced steatosis. All patients with acute liver injury were identified (visit 1) and followed for >30 days (visit 2). Correlation analyses were performed to determine potential associations. Key Results Drug‐induced liver injury, autoimmune hepatitis and viral hepatitis patients had higher levels of LBP, CD14, CD163, MCSF‐1R (CSFR) and ICAM‐1 and significantly lower levels of MAdCAM‐1 and zonulin at detection of liver injury compared with healthy controls or the second visit. Drug‐induced steatosis and MASLD patients had increased levels of S100A9, S100A12 and zonulin. MASLD patients with significant fibrosis (F2–F4) also had higher levels of CD163 and MCSF‐1R. No difference was found between drug‐induced steatosis and MASLD with no or low fibrosis. Conclusion and Implications Our results highlight similarities in macrophage activation, intestinal barrier dysfunction and translocation of bacterial products in liver injury of various aetiologies. A better understanding of the pathophysiological mechanisms may aid the development of targeted therapies for liver inflammation and fibrosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- UGC Aparato Digestivo, Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
- Centro de investigación en red en el área temática de enfermedades hepáticas y digestivas (CIBERehd), Madrid, Spain.
Funding
- Sara Borrell Research Contract (ISCIII)
- HORIZON-HLTH-2022-STAYHLTH-02
- Instituto de Salud Carlos III - European Union and Fondo Europeo de Desarrollo Regional - FEDER
- i-PFIS: Doctorados IIS-empresa en Ciencias y Tecnologías de la Salud (ISCIII)
Cite
APA
Di Zeo-Sánchez, D. E., Díaz-Alberola, I., Pinazo-Bandera, J. M., García-Cortés, M., Sanabria-Cabrera, J., Robles-Díaz, M., Álvarez-Álvarez, I., Lucena, M. I., Andrade, R. J., Villanueva-Paz, M., & Stephens, C. (2025). Intestinal permeability and immune‐inflammatory markers in patients with idiosyncratic drug‐induced liver injury, drug‐induced steatosis and metabolic dysfunction–associated steatotic liver disease (MASLD). British Journal of Pharmacology, 182(21), 5303-5316. https://doi.org/10.1111/bph.70123
Vancouver
Di Zeo-Sánchez DE, Díaz-Alberola I, Pinazo-Bandera JM, García-Cortés M, Sanabria-Cabrera J, Robles-Díaz M, et al. Intestinal permeability and immune‐inflammatory markers in patients with idiosyncratic drug‐induced liver injury, drug‐induced steatosis and metabolic dysfunction–associated steatotic liver disease (MASLD). British Journal of Pharmacology. 2025;182(21):5303-5316. doi:10.1111/bph.70123
BibTeX
@article{DiZeoSnchez2025,
author = {Di Zeo-Sánchez, Daniel E and Díaz-Alberola, Irene and Pinazo-Bandera, José María and García-Cortés, Miren and Sanabria-Cabrera, Judith and Robles-Díaz, Mercedes and Álvarez-Álvarez, Ismael and Lucena, M Isabel and Andrade, Raúl J and Villanueva-Paz, Marina and Stephens, Camilla},
title = {Intestinal permeability and immune‐inflammatory markers in patients with idiosyncratic drug‐induced liver injury, drug‐induced steatosis and metabolic dysfunction–associated steatotic liver disease (MASLD)},
journal = {British Journal of Pharmacology},
year = {2025},
volume = {182},
number = {21},
pages = {5303--5316},
doi = {10.1111/bph.70123}
}
EUVIMED